Themes and variations on ubiquitylation

Nature Reviews Molecular Cell Biology

Volumn 2, Issue 3, 2001, Pages 169-178

  Weissman, Allan M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EUKARYOTA;

CBL PROTEIN; CBL PROTEIN, HUMAN; LIGASE; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN; PROTEIN MDM2; UBE2L3 PROTEIN, HUMAN; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE;

ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; REVIEW;

ANIMALS; BINDING SITES; HUMANS; LIGASES; MODELS, MOLECULAR; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-CBL; PROTO-ONCOGENE PROTEINS C-MDM2; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 0035292759     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/35056563     Document Type: Review

References (107)

1. Thrower, J. S., Hoffman, L., Rechsteiner, M. & Pickart, C. M. Recognition of the polyubiquitin proteolytic signal. EMBO J. 19, 94-102 (2000).
2. Loeb, K. R. & Haas, A. L. Conjugates of ubiquitin cross-reactive protein distribute in a cytoskeletal pattern. Mol. Cell. Biol. 14, 8408-8419 (1994).
3. Jentsch, S. & Pyrowolakis, G. Ubiquitin and its kin: how close are the family ties? Trends Cell Biol. 10, 335-342 (2000).
4. Yeh, E. T., Gong, L. & Kamitani, T. Ubiquitin-like proteins: new wines in new bottles. Gene 248, 1-14 (2000).
5. Kleijnen, M. F. et al. The hPLIC proteins may provide a link between the ubiquitination machinery and the proteasome. Mol. Cell 6, 409-419 (2000).
6. Huibregtse, J. M., Scheffner, M., Beaudenon, S. & Howley, P. M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl Acad. Sci. USA. 92, 2563-2567 (1995).
7. Joazeiro, C. A. & Weissman, A. M. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102, 549-552 (2000).
8. Finley, D., Bartel, B. & Varshavsky, A. The tails of ubiquitin precursors are ribosomal proteins whose fusion to ubiquitin facilitates ribosome biogenesis. Nature 338, 394-401 (1989).
9. Wilkinson, K. D. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin. Cell. Dev. Biol. 11, 141-148 (2000).
10. Handley-Gearhart, P. M., Stephen, A. G., Trausch-Azar, J. S., Ciechanover, A. & Schwartz, A. L. Human ubiquitin-activating enzyme, E1. Indication of potential nuclear and cytoplasmic subpopulations using epitope-tagged cDNA constructs. J. Biol. Chem. 269, 33171-33178 (1994).
11. Nagai, Y. et al. Ubiquitin-activating enzyme, E1, is phosphorylated in mammalian cells by the protein kinase Cdc2. J. Cell Sci. 108, 2145-2152 (1995).
12. Grenfell, S. J., Trausch-Azar, J. S., Handley-Gearhart, P. M., Ciechanover, A. & Schwartz, A. L. Nuclear localization of the ubiquitin-activating enzyme, E1, is cell-cycle-dependent. Biochem. J. 300, 701-708 (1994).
13. Finley, D., Ciechanover, A. & Varshavsky, A. Thermolability of ubiquitin-activating enzyme from the mammalian cell cycle mutant ts85. Cell 37, 43-55 (1984). This is a landmark study that provided the first evidence of a role for the ubiquitin-conjugating system in cellular function.
14. Mathias, N., Steussy, C. N. & Goebl, M. G. An essential domain within Cdc34p is required for binding to a complex containing Cdc4p and Cdc53p in Saccharomyces cerevisiae. J. Biol. Chem. 273, 4040-4045 (1998).
15. Xie, Y. & Varshavsky, A. The E2-E3 interaction in the N-end rule pathway: the RING-H2 finger of E3 is required for the synthesis of multiubiquitin chain. EMBO J. 18, 6832-6844 (1999). This study establishes a role for the RING finger in the activity of the N-end rule E3.
16. Sommer, T. & Jentsch, S. A protein translocation defect linked to ubiquitin conjugation at the endoplasmic reticulum. Nature 365, 176-179 (1993). This study describes Ubc6 and provided the first suggestion of a linkage between the ubiquitin-conjugating system and the degradation of proteins from the endoplasmic reticulum.
17. Hauser, H. P., Bardroff, M., Pyrowolakis, G. & Jentsch, S. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J. Cell Biol. 141, 1415-1422 (1998).
18. Gonen, H. et al. Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of IκBα. J. Biol. Chem. 274, 14823-14830 (1999).
19. Schwarz, S. E. Rosa, J. L. & Scheffner, M. Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7. J. Biol. Chem. 273, 12148-12154 (1998).
20. Haas, A. L. & Siepmann, T. J. Pathways of ubiquitin conjugation. FASEB J. 11, 1257-1268 (1997).
21. Huang, L. et al. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 286, 1321-1326 (1999).
22. Zheng, N., Wang, P., Jeffrey, P. D. & Pavletich, N. P. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102, 533-539 (2000). References 21 and 22 describe the crystal structures of a HECT domain and a RING finger protein with an E2.
23. Nuber, U. & Scheffner, M. Identification of determinants in E2 ubiquitin-conjugating enzymes required for hect E3 ubiquitin-protein ligase interaction. J. Biol. Chem. 274, 7576-7582 (1999).
24. Cook, W. J., Martin, P. D., Edwards, B. F., Yamazaki, R. K. & Chau, V. Crystal structure of a class I ubiquitin conjugating enzyme (Ubc7) from Saccharomyces cerevisiae at 2.9 angstroms resolution. Biochemistry 36, 1621-1627 (1997).
25. Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505 (1993). This is a seminal paper describing the characterization of E6-AP, the first described member of the HECT domain family of E3s.
26. Kumar, S., Talis, A. L. & Howley, P. M. Identification of HHR23A as a substrate for E6-associated protein-mediated ubiquitination. J. Biol. Chem. 274, 18785-18792 (1999).
27. Kishino, T., Lalande, M. & Wagstaff, J. UBE3A/E6-AP mutations cause Angelman syndrome. Nature Genet. 15, 70-73 (1997).
28. Kay, B. K., Williamson, M. P. & Sudol, M. The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J. 14, 231-241 (2000).
29. Rotin, D., Staub, O. & Haguenauer-Tsapis, R. Ubiquitination and endocytosis of plasma membrane proteins: role of Nedd4/Rsp5p family of ubiquitin-protein ligases. J. Membr. Biol. 176, 1-17 (2000).
30. Plant, P. J. et al. Apical membrane targeting of Nedd4 is mediated by an association of its C2 domain with annexin XIIIb. J. Cell Biol. 149, 1473-1484 (2000).
31. Hoppe, T. et al. Activation of a membrane-bound transcription factor by regulated ubiquitin/proteasome-dependent processing. Cell 102, 577-586 (2000).
32. Orian, A. et al. Ubiquitin-mediated processing of NF-κB transcriptional activator precursor p105. Reconstitution of a cell-free system and identification of the ubiquitin-carrier protein, E2, and a novel ubiquitin-protein ligase, E3, involved in conjugation. J. Biol. Chem. 270, 21707-21714 (1995).
33. Bonifacino, J. S. & Weissman, A. M. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu. Rev. Cell. Dev. Biol. 14, 19-57 (1998).
34. + channel. FASEB J. 15, 204-214 (2001).
35. Freemont, P. S. RING for destruction? Curr. Biol. 10, R84-R87 (2000).
36. Kamura, T. et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284, 657-661 (1999).
37. Ohta, T., Michel, J. J., Schottelius, A. J. & Xiong, Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol. Cell 3, 535-541 (1999).
38. Tan, P. et al. Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of IκBα. Mol. Cell 3, 527-533 (1999).
39. Skowyra, D. et al. Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1. Science 284, 662-665 (1999).
40. Seol, J. H. et al. Cdc53/cullin and the essential hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme cdc34. Genes Dev. 13, 1614-1626 (1999). References 36-40 all describe the characterization of a small RING finger protein as an integral component of SCF E3s.
41. Lorick, K. L. et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl Acad. Sci. USA 96, 11364-11369 (1999). This study suggests a general role for RING fingers in ubiquitylation.
42. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. & Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945-8951 (2000).
43. Honda, R. & Yasuda, H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19, 1473-1476 (2000).
44. Waterman, H., Levkowitz, G., Alroy, I. & Yarden, Y. The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J. Biol. Chem. 274, 22151-22154 (1999).
45. Joazeiro, C. A. et al. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286, 309-312 (1999).
46. Yokouchi, M. et al. Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J. Biol. Chem. 274, 31707-31712 (1999).
47. Hu, G. & Fearon, E. R. Siah-1 N-terminal RING domain is required for proteolysis function, and C-terminal sequences regulate oligomerization and binding to target proteins. Mol. Cell. Biol. 19, 724-732 (1999). References 42-47 demonstrate a role for the RING finger in a variety of known and suspected E3s.
48. Zachariae, W. et al. Mass spectrometric analysis of the anaphase-promoting complex from yeast: identification of a subunit related to cullins. Science 279, 1216-1219 (1998).
49. Brzovic, P. S., Meza, J., King, M. C. & Klevit, R. E. The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain. J. Biol. Chem. 273, 7795-7799 (1998).
50. Yang, Y., Fang, S., Jensen, J. P., Weissman, A. M. & Ashwell, J. D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288, 874-877 (2000).
51. Hwang, H. K. et al. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J. Biol. Chem. 275, 26661-26664 (2000).
52. Shimura, H. et al. Familial Parkinson's disease gene product, Parkin, in a ubiquitin-protein ligase. Nature Genet. 25, 302-305 (2000).
53. Zhang, Y. et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA 97, 13354-13359 (2000).
54. Leverson, J. D. et al. The APC11 RING-H2 finger mediates E2-dependent ubiquitination. Mol. Biol. Cell 11, 2315-2325 (2000).
55. Deshaies, R. J. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell. Dev. Biol. 15, 435-467 (1999).
56. Page, A. M. & Hieter, P. The anaphase-promoting complex: new subunits and regulators. Annu. Rev. Biochem. 68, 583-609 (1999).
57. Tyers, M. & Jorgensen, P. Proteolysis and the cell cycle: with this RING I do thee destroy. Curr. Opin. Genet. Dev. 10, 54-64 (2000).
58. Bai, C. et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86, 263-274 (1996).
59. Zhou, P., Bogacki, R., McReynolds, L. & Howley, P. M. Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol. Cell 6, 751-756 (2000).
60. Met30-mediated inactivation of the transcription factor Met4. Cell 102, 303-314 (2000).
61. Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M. & Krek, W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13, 1822-1833 (1999).
62. Iwai, K. et al. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl Acad. Sci. USA 96, 12436-12441 (1999).
63. Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nature Cell Biol. 2, 423-427 (2000).
64. Cockman, M. E. et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733-25741 (2000).
65. Kamura, T. et al. Activation of HIF1α ubiquitination by a reconstituted von hippel-lindau (VHL) tumor suppressor complex. Proc. Natl Acad. Sci. USA 97, 10430-10435 (2000). References 61-65 establish the VHL-CBC complex as an E3 and show that HIF1α is a substrate.
66. Kamura, T. et al. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras. WD-40 repeat, and ankyrin repeat families. Genes Dev. 12, 3872-3881 (1998).
67. Chung, C. H. & Baek, S. H. Deubiquitinating enzymes: their diversity and emerging roles. Biochem. Biophys. Res. Commun. 266, 633-640 (1999).
68. Papa, F. R. & Hochstrasser, M. The yeast DOA4 gene encodes a deubiquitinating enzyme related to a product of the human tre-2 oncogene. Nature 366, 313-319 (1993).
69. Lam, Y. A., Xu, W., DeMartino, G. N. & Cohen, R. E. Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome. Nature 385, 737-740 (1997).
70. Koegl, M. et al. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96, 635-644 (1999).
71. Spence, J., Sadis, S., Haas, A. L. & Finley, D. A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol. Cell. Biol. 15, 1265-1273 (1995).
72. Hofmann, R. M. & Pickart, C. M. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell 96, 645-653 (1999).
73. Baily, V., Lauder, S., Prakash, S. & Prakash, L. Yeast DNA repair proteins Rad6 and Rad18 form a heterodimer that has ubiquitin conjugating, DNA binding, and ATP hydrolytic activities. J. Biol. Chem. 272, 23360-23365 (1997).
74. Ulrich, H. D. & Jentsch, S. Two RING finger proteins mediate cooperation between ubiquitin-conjugating enzymes in DNA repair. EMBO J. 19, 3388-3397 (2000).
75. Spence, J. et al. Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell 102, 67-76 (2000). This is provocative study that demonstrates a role for K63-linked multi-ubiquitin chains in regulating translation.
76. Deng, L. et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351-361 (2000).
77. Chau, V. et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243, 1576-1583 (1989).
78. Baldi, L., Brown, K., Franzoso, G. & Siebenlist, U. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of IκBα. J. Biol. Chem. 271, 376-379 (1996).
79. Hou, D., Cenciarelli, C., Jensen, J. P., Nguyen, H. B. & Weissman, A. M. Activation-dependent ubiquitination a T cell antigen receptor subunit on multiple intracellular lysines. J. Biol. Chem. 269, 14244-14247 (1994).
80. Treier, M., Staszewski, L. M. & Bohmann, D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78, 787-793 (1994).
81. Breitschopf, K., Bengal, E., Ziv, T., Admon, A. & Ciechanover, A. A novel site for ubiquitination: the N-terminal residue, and not internal lysines of MyoD, is essential for conjugation and degradation of the protein. EMBO J. 17, 5964-5973 (1998).
82. Cp1 ubiquitination. Mol. Cell 5, 403-410 (2000). This study provides strong evidence for ubiquitin-independent proteasomal degradation of a protein that is known to ubiquitylated.
83. van Nocker, S. et al. The multiubiquitin-chain-binding protein Mcb1 is a component of the 26S proteasome in Saccharomyces cerevisiae and plays a nonessential, substrate-specific role in protein turnover. Mol. Cell. Biol. 16, 6020-6028 (1996).
84. Brodsky, J. L. & McCracken, A. A. ER protein quality control and proteasome-mediated protein degradation. Semin. Cell Dev. Biol. 10, 507-513 (1999).
85. Unger, T. et al. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene 18, 3205-3212 (1999).
86. Shieh, S. Y., Taya, Y. & Prives, C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J. 18, 1815-1823 (1999).
87. Lohrum, M. A., Ashcroft, M., Kubbutat, M. H. & Vousden, K. H. Identification of a cryptic nucleolar-localization signal in MDM2. Nature Cell Biol. 2, 179-181 (2000).
88. Weber, J. D. et al. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol. Cell. Biol. 20, 2517-2528 (2000).
89. ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19, 2312-2323 (2000).
90. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18, 22-27 (1999).
91. Jackson, M. W. & Berberich, S. J. MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell. Biol. 20, 1001-1007 (2000).
92. Sharp, D. A., Kratowicz, S. A., Sank, M. J. & George, D. L. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 274, 38189-38196 (1999).
93. Tanimura, S. et al. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447, 5-9 (1999).
94. Buschmann, T., Fuchs, S. Y., Lee, C.-G., Pan, Z.-Q. & Ronai, Z. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell 101, 753-762 (2000).
95. Balint, E., Bates, S. & Vousden, K. H. Mdm2 binds p73α without targeting degradation. Oncogene 18, 3923-3929 (1999).
96. Dobbelstein, M., Wienzek, S., Konig, C. & Roth, J. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18, 2101-2106 (1999).
97. Zeng, X. et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 19, 3257-3256 (1999).
98. Lam, Y. A. et al. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc. Natl Acad. Sci. USA. 97, 9902-9906 (2000).
99. kp1. Biochem. Biophys. Res. Commun. 270, 1093-1096 (2000).
100. Osaka, F. et al. Covalent modifier NEDD8 is essential for SCF ubiquitin-ligase in fission yeast. EMBO J. 19, 3475-3484 (2000).
101. Podust, V. N. et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc. Natl Acad. Sci. USA 97, 4579-4584 (2000).
102. Read, M. A. et al. Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha. Mol. Cell. Biol. 20, 2326-2333 (2000).
103. Wada, H., Yeh, E. T. & Kamitani, T. A dominant-negative UBC12 mutant sequesters NEDD8 and inhibits NEDD8 conjugation in vivo. J. Biol. Chem. 275, 17008-17015 (2000).
104. Wu, K., Chen, A. & Pan, Z. Q. Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J. Biol. Chem. 275, 32317-32324 (2000).
105. Liakopoulos, D., Doenges, G., Matuschewski, K. & Jentsch, S. A novel protein modification pathway related to the ubiquitin system. EMBO J. 17, 2208-2214 (1998).
106. Liakopoulos, D., Busgen, T., Brychzy, A., Jentsch, S. & Pause, A. Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. Proc. Natl Acad. Sci. USA 96, 5510-5515 (1999).
107. Gmachl, M., Gieffers, C., Podtelejnikov, A. V., Mann, M. & Peters, J. M. The RING-H2 finger protein APC11 and the E2 enzyme UBC4 are sufficient to ubiquitinate substrates of the anaphase-promoting complex. Proc. Natl Acad. Sci. USA 97, 8973-8978 (2000).